Related Experiment Videos
Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role
J F Schoeman1, P Springer, A Ravenscroft
1Department of Paediatrics and Child Health, University of Stellenbosch and Tygerberg Hospital, South Africa. jfs@gerga.sun.ac.za
Abstract:
The objective of this study was to determine the safety and tolerability of the immunomodulatory agent thalidomide as adjunct therapy in children with tuberculous meningitis. Children with stage 2 tuberculous meningitis received oral thalidomide for 28 days in a dose-escalating study, in addition to standard four-drug antituberculosis therapy, corticosteroids, and specific treatment of complications such as raised intracranial pressure. Clinical and laboratory evaluations were carried out. Fifteen patients (median age, 34 months) were enrolled. Thalidomide was administered via nasogastric tube in a dosage of 6 mg/kg/day, 12 mg/kg/day, or 24 mg/kg/day. The only adverse events possibly related to the study drug were transient skin rashes in two patients. Levels of tumor necrosis factor-alpha in the cerebrospinal fluid decreased markedly during thalidomide therapy. Clinical outcome and neurologic imaging showed greater improvement than that experienced with historical controls. Thalidomide appeared safe and well tolerated in children with stage 2 tuberculous meningitis and could have important anti-inflammatory effects. These promising results have led us to embark on a randomized, double-blind, placebo-controlled trial of the efficacy of thalidomide in tuberculous meningitis.
Insights
Thalidomide, an immunomodulatory drug, was found safe and well-tolerated as an add-on treatment for children with tuberculous meningitis. It reduced inflammation and showed promising clinical outcomes, warranting further study.
Area of Science:
- Pediatric Infectious Diseases
- Neuroimmunology
- Pharmacology
Background:
- Tuberculous meningitis (TBM) is a severe infection requiring multifaceted treatment.
- Adjunct therapies are explored to improve outcomes in TBM, particularly for managing inflammation.
Purpose of the Study:
- To evaluate the safety and tolerability of thalidomide as an adjunct therapy in children with stage 2 TBM.
- To assess the impact of thalidomide on inflammatory markers and clinical outcomes.
Main Methods:
- A dose-escalating study involving 15 children with TBM receiving thalidomide for 28 days alongside standard anti-TB therapy and corticosteroids.
- Clinical and laboratory assessments, including cerebrospinal fluid tumor necrosis factor-alpha levels, were performed.
- Dosages ranged from 6 to 24 mg/kg/day administered via nasogastric tube.
Main Results:
- Thalidomide was safe and well-tolerated, with only transient skin rashes as possible adverse events.
- Significant reduction in cerebrospinal fluid tumor necrosis factor-alpha levels observed.
- Improved clinical outcomes and neurologic imaging compared to historical controls.
Conclusions:
- Thalidomide shows potential as an anti-inflammatory agent in pediatric TBM.
- The drug is safe and well-tolerated in this patient population.
- Results support further investigation in a randomized controlled trial.